Influência da suplementação aguda de melatonina na resposta de hormônios anabólicos ao exercício físico aeróbio: um estudo randomizado controlado por placebo
Nenhuma Miniatura disponível
Data
2024-06-03
Autores
Damiani, Gianlucca Nadas [UNIFESP]
Orientadores
Antunes, Hanna Karen Moreira [UNIFESP]
Tipo
Dissertação de mestrado
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Objetivos: Investigar os efeitos da suplementação de Melatonina (MEL) aguda na secreção de hormônios anabólicos após a realização de exercício físico aeróbio. Métodos: Em estudo transversal, randomizado por sorteio, duplo-cego, cross-over e placebo-controlado, 13 voluntários saudáveis e fisicamente ativos foram submetidos a duas visitas experimentais à tarde, na qual realizaram exercício aeróbio em esteira ergométrica que consistiu em 20 minutos a 60% da Vpico, seguido de teste time-trial de 1,5 km na presença ou ausência de melatonina (10mg). As amostras sanguíneas foram coletadas nos momentos basal (BAS), imediatamente após o exercício moderado (CONT), imediatamente após o time-trial (TT), 30 minutos (REC) após exercício e 24 horas (POS24) após a suplementação, para dosagem de hormônio do crescimento (GH), testosterona livre e total, insulina, IGF-1, hormônio luteinizante (LH) e proteína ligadora 3 do IGF-1 (IGFBP-3). Resultados: A melatonina não impactou o desempenho para a realização do teste time-trial (p>0,05), nem a resposta de GH, testosterona, insulina, LH ou IGFBP-3 ao esforço que foram similares entre as condições de suplementação. Apesar disso, na presença de MEL a resposta de IGF-1 ao esforço foi aumentada de forma significativa (CONT - p=0,004 vs. BAS; TT - p=0,003 vs. BAS), que não foi observada na condição placebo. Mesmo sem efeitos durante o exercício, na presença de MEL, as concentrações de LH se elevaram após 30 minutos de recuperação (p=0,041 vs. CONT; p=0,036 vs. TT) e houve decréscimo nas concentrações de IGFBP-3 no mesmo ponto quando comparado ao exercício intenso (p =0,021 vs. TT), que não foram observados com placebo. Conclusão: A suplementação única de melatonina a 10 mg previamente à realização de exercício aeróbio parece potencializar a resposta aguda de IGF-1 ao esforço realizado, sem aumento concomitante de IGFBP-3 ou impacto sobre o desempenho.
Objectives: To investigate the effects of acute melatonin (MEL) supplementation on the secretion of anabolic hormones after aerobic exercise. Methods: In a cross-sectional, randomized, double-blind, crossover, and placebo-controlled study, 13 healthy and physically active males underwent two experimental visits in the afternoon (14h00), during which they performed a running test on a treadmill consisting of 20 minutes at 60% of Vpeak, followed by a 1.5 km time-trial test in the presence or absence of melatonin (10mg). Blood samples were collected at baseline (BAS), immediately after moderate exercise (CONT), immediately after the time-trial (TT), 30 minutes after exercise (REC), and 24 hours after supplementation (POS24), for the measurement of growth hormone (GH), free and total testosterone, insulin, IGF-1, luteinizing hormone (LH), and insulin-like growth factor binding protein 3 (IGFBP-3). Results: Melatonin did not impact performance for the time-trial test (p>0.05), nor the response of GH, testosterone, insulin, LH, or IGFBP-3 to exercise, which were similar between supplementation conditions. However, in the presence of MEL, the response of IGF-1 to exercise was significantly increased (CONT - p=0.004 vs. BAS; TT - p=0.003 vs. BAS), which was not observed in the placebo condition. Even without effects during exercise, in the presence of MEL, LH concentrations increased after 30 minutes of recovery (p=0.041 vs. CONT; p=0.036 vs. TT), and there was a decrease in IGFBP-3 concentrations at the same point compared to intense exercise (p=0.021 vs. TT), which was not observed with placebo. Conclusion: Acute supplementation of 10 mg melatonin in the afternoon prior to aerobic exercise appears to enhance the acute response of IGF-1 to exercise, without a concomitant increase in IGFBP-3 or impact on performance.
Objectives: To investigate the effects of acute melatonin (MEL) supplementation on the secretion of anabolic hormones after aerobic exercise. Methods: In a cross-sectional, randomized, double-blind, crossover, and placebo-controlled study, 13 healthy and physically active males underwent two experimental visits in the afternoon (14h00), during which they performed a running test on a treadmill consisting of 20 minutes at 60% of Vpeak, followed by a 1.5 km time-trial test in the presence or absence of melatonin (10mg). Blood samples were collected at baseline (BAS), immediately after moderate exercise (CONT), immediately after the time-trial (TT), 30 minutes after exercise (REC), and 24 hours after supplementation (POS24), for the measurement of growth hormone (GH), free and total testosterone, insulin, IGF-1, luteinizing hormone (LH), and insulin-like growth factor binding protein 3 (IGFBP-3). Results: Melatonin did not impact performance for the time-trial test (p>0.05), nor the response of GH, testosterone, insulin, LH, or IGFBP-3 to exercise, which were similar between supplementation conditions. However, in the presence of MEL, the response of IGF-1 to exercise was significantly increased (CONT - p=0.004 vs. BAS; TT - p=0.003 vs. BAS), which was not observed in the placebo condition. Even without effects during exercise, in the presence of MEL, LH concentrations increased after 30 minutes of recovery (p=0.041 vs. CONT; p=0.036 vs. TT), and there was a decrease in IGFBP-3 concentrations at the same point compared to intense exercise (p=0.021 vs. TT), which was not observed with placebo. Conclusion: Acute supplementation of 10 mg melatonin in the afternoon prior to aerobic exercise appears to enhance the acute response of IGF-1 to exercise, without a concomitant increase in IGFBP-3 or impact on performance.
Descrição
Citação
DAMIANI, Gianlucca Nadas. Influência da suplementação aguda de melatonina na resposta de hormônios anabólicos ao exercício físico aeróbio: um estudo randomizado controlado por placebo. 2024. 90 f. Dissertação (Mestrado em Psicobiologia) – Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, 2024.